A Phase 4 interventional study of Placebo & Aspirin and Clopidogrel & Aspirin, Prasugrel & Aspirin in Coronary Artery Disease, sponsored by Baim Institute for Clinical Research. Completed at 256 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-09.
Sponsored by Baim Institute for Clinical Research · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies testing clopidogrel in Coronary Artery Disease — 3 open to participants now, 3 under way, 1 of them phase 3. Clopidogrel · Coronary Artery Disease.
Among the 71 studies testing clopidogrel in Coronary Artery Disease, this one has the largest enrollment, is one of 8 that started in 2009, is one of 53 in phase 4, and was the 25th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →3 of the 71 studies testing clopidogrel in Coronary Artery Disease are open now, in 3 countries. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
St. Antonius Hospital · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 8 · Phase 4 53
First in 2004; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25,682 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 120 across the 71 interventional studies. Of the 57 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 71 have an industry lead sponsor. The 10 most frequent:
Baim Institute for Clinical Research is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Baim Institute for Clinical Research has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
2 of the studies testing clopidogrel in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT07025148University of FloridaDual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 71 studies testing clopidogrel in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.
Subjects with ischemic heart disease due to stenotic lesions in either native coronary arteries or coronary artery bypass grafts undergoing percutaneous coronary intervention (PCI) with stent placement and no contraindications to prolonged dual antiplatelet therapy are eligible to be enrolled in the study.
All enrolled subjects will undergo PCI with stent placement. All enrolled subjects will be treated with either an FDA-approved drug eluting stent(s) (DES) or an FDA-approved bare metal stent(s) (BMS) (per their respective Instructions for Use) and assigned to 12 months of open label FDA-approved thienopyridine treatment in addition to aspirin. Operators will select the thienopyridine according to the package insert. Thienopyridine treatment dose will be according to the standard of practice and prescribing information for the selected medication. Aspirin treatment will be 75-325 mg for the first 6 months after the procedure and 75-162 mg subsequently, to be continued indefinitely. All DES or BMS subjects who are treated with 12 months of dual antiplatelet therapy post index procedure and who are event free per protocol will be eligible for randomization to either placebo (12 m DAPT Study arm) or an additional 18 months of thienopyridine treatment (30 m DAPT Study arm). Both arms will continue aspirin therapy.
Up to four (4) separate post-market approval studies will be allowed to incorporate the randomized design of the DAPT Study for a subset of subjects who may then be contributed for the DAPT Study analyses.
Inclusion Criteria (Enrollment):
Inclusion Criterion (Randomization at 12 months):
Exclusion Criteria (Enrollment):
Exclusion Criteria (Randomization at 12 months):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Drug: Placebo & Aspirin
This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug pages: Clopidogrel · Aspirin · Prasugrel
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.
Time frame: 18 months (12-30 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.
Time frame: 18 months (12-30 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Time frame: 18 months (12-30 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS
Secondary powered endpoint
Time frame: 33 months (0-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS
Secondary powered endpoint
Time frame: 33 months (0-33 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
Time frame: 21 months (12-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Time frame: 21 months (12-33 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Time frame: 21 months (12-33 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Time frame: 18 months (12-30 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Time frame: 18 months (12-30 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Time frame: 18 months (12-30 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Time frame: 21 months (12-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Time frame: 21 months (12-33 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Time frame: 21 months (12-33 months post-index procedure)
Between 08/13/2009 and 07/01/2011, a total of 25682 patients were enrolled into the DAPT Study either by HCRI (NCT00977938; 14491 pts) or from 1 of 4 PMS studies: Abbott Xience V US (NCT01106534; 2998 pts), Boston Scientific Liberté PAS (NCT00997503; 3904 pts), Cordis CYPRESS (NCT00954707; 2029 pts) and Medtronic EDUCATE (NCT01069003; 2260 pts).
| Milestone | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|---|---|
| Started | 5020 | 4941 | 842 | 845 |
| Completed | 4783 | 4716 | 796 | 784 |
| Not completed | 237 | 225 | 46 | 61 |
| Withdrew: Withdrawal by subject | 132 | 116 | 13 | 20 |
| Withdrew: Lost to follow-up | 88 | 91 | 30 | 37 |
| Withdrew: Other | 17 | 18 | 3 | 4 |
| Milestone | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|---|---|
| Started | 4783 | 4716 | 796 | 784 |
| Completed | 4732 | 4658 | 784 | 781 |
| Not completed | 51 | 58 | 12 | 3 |
| Withdrew: Withdrawal by subject | 9 | 12 | 2 | 0 |
| Withdrew: Lost to follow-up | 34 | 42 | 10 | 3 |
| Withdrew: Other | 8 | 4 | 0 | 0 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.
| percentage of patients (KM estimate) | DES 30-month DAPT | DES 12-month DAPT |
|---|---|---|
| MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT | 4.34 | 5.92 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.
| percentage of patients (KM estimate) | DES 30-month DAPT | DES 12-month DAPT |
|---|---|---|
| Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT | 0.40 | 1.35 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
| percentage of patients | DES 30-month DAPT | DES 12-month DAPT |
|---|---|---|
| GUSTO Severe or Moderate Bleeding - Randomized DES ITT | 2.53 | 1.57 |
Secondary powered endpoint
| percentage of patients | Propensity-matched DES | Propensity-matched BMS |
|---|---|---|
| MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS | 11.37 | 13.24 |
Secondary powered endpoint
| percentage of patients | Propensity-matched DES | Propensity-matched BMS |
|---|---|---|
| Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS | 1.70 | 2.61 |
| percentage of patients (KM estimate) | DES 30-month DAPT | DES 12-month DAPT |
|---|---|---|
| MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT | 5.62 | 6.49 |
ST was assessed according to the Academic Research Consortium (ARC) definitions.
| percentage of patients (KM estimate) | DES 30-month DAPT | DES 12-month DAPT |
|---|---|---|
| Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT | 0.69 | 1.45 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
| percentage of patients | DES 30-month DAPT | DES 12-month DAPT |
|---|---|---|
| GUSTO Severe or Moderate Bleeding - Randomized DES ITT | 2.74 | 1.88 |
| percentage of patients (KM estimate) | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|
| MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT | 4.04 | 4.69 |
ST was assessed according to the Academic Research Consortium (ARC) definitions.
| percentage of patients (KM estimate) | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|
| Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT | 0.50 | 1.11 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
| percentage of patients | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|
| GUSTO Severe or Moderate Bleeding - Randomized BMS ITT | 2.03 | 0.90 |
| percentage of patients (KM estimate) | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|
| MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT | 4.68 | 5.48 |
ST was assessed according to the Academic Research Consortium (ARC) definitions.
| percentage of patients (KM estimate) | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|
| Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT | 0.50 | 1.11 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
| percentage of patients | BMS 30-month DAPT | BMS 12-month DAPT |
|---|---|---|
| GUSTO Severe or Moderate Bleeding - Randomized BMS ITT | 2.09 | 1.05 |
Collected over 12-33 months post-index procedure (randomization to 33 months post-index procedure). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HCRI DAPT - DES 30-month DAPT | — | 617/2,642 (23.4%) | — |
| HCRI DAPT - DES 12-month DAPT | — | 572/2,634 (21.7%) | — |
| HCRI DAPT - BMS 30-month DAPT | — | 144/842 (17.1%) | — |
| HCRI DAPT - BMS 12-month DAPT | — | 150/845 (17.8%) | — |
| Event | HCRI DAPT - DES 30-month DAPT | HCRI DAPT - DES 12-month DAPT | HCRI DAPT - BMS 30-month DAPT | HCRI DAPT - BMS 12-month DAPT |
|---|---|---|---|---|
| ANGINA PECTORISCardiac disorders | 55/2642 | 55/2634 | 13/842 | 18/845 |
| NON-CARDIAC CHEST PAINGeneral disorders | 54/2642 | 51/2634 | 12/842 | 15/845 |
| CHEST PAINGeneral disorders | 43/2642 | 45/2634 | 12/842 | 7/845 |
| ANGINA UNSTABLECardiac disorders | 27/2642 | 40/2634 | 4/842 | 5/845 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 29/2642 | 25/2634 | 7/842 | 5/845 |
| CORONARY ARTERY DISEASECardiac disorders | 22/2642 | 16/2634 | 9/842 | 6/845 |
| ATRIAL FIBRILLATIONCardiac disorders | 24/2642 | 14/2634 | 3/842 | 9/845 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 22/2642 | 14/2634 | 4/842 | 5/845 |
| SYNCOPENervous system disorders | 10/2642 | 9/2634 | 7/842 | 3/845 |
| PNEUMONIAInfections and infestations | 21/2642 | 17/2634 | 4/842 | 4/845 |
| Event | HCRI DAPT - DES 30-month DAPT | HCRI DAPT - DES 12-month DAPT | HCRI DAPT - BMS 30-month DAPT | HCRI DAPT - BMS 12-month DAPT |
|---|---|---|---|---|
| AEs were not collected in the DAPT TrialCardiac disorders | — | — | — | — |
| Age, Continuous(years) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| Mean | 61.84 ± 10.18 | 61.60 ± 10.12 | 58.86 ± 10.54 | 59.18 ± 11.07 | 61.33 ± 10.29 |
| Sex: Female, Male(Participants) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| Female | 1242 | 1284 | 215 | 184 | 2925 |
| Male | 3778 | 3657 | 627 | 661 | 8723 |
| Race/Ethnicity, Customized(participants) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 17 | 41 | 0 | 2 | 60 |
| Asian | 48 | 35 | 3 | 2 | 88 |
| Black or African American | 252 | 253 | 38 | 33 | 576 |
| Native Hawaiian or Other Pacific Islander | 13 | 9 | 1 | 1 | 24 |
| White | 4480 | 4428 | 768 | 774 | 10450 |
| Other | 108 | 106 | 20 | 23 | 257 |
| Region of Enrollment(participants) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| North America | 4502 | 4416 | 509 | 519 | 9946 |
| Europe | 402 | 405 | 304 | 300 | 1411 |
| Australia | 47 | 55 | 14 | 12 | 128 |
| New Zealand | 69 | 65 | 15 | 14 | 163 |
| weight(kg) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| Mean | 91.49 ± 19.74 | 91.52 ± 19.43 | 87.99 ± 18.40 | 88.54 ± 18.77 | 91.04 ± 19.48 |
| Body Mass Index (BMI)(kg/m2) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| Mean | 30.54 ± 5.79 | 30.55 ± 5.77 | 29.49 ± 5.18 | 29.61 ± 5.55 | 30.40 ± 5.73 |
| Diabetes Mellitus(participants) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| Number | 1556 | 1481 | 181 | 173 | 3391 |
| Hypertension(participants) | DES 30-month DAPT | DES 12-month DAPT | BMS 30-month DAPT | BMS 12-month DAPT | Total |
|---|---|---|---|---|---|
| Number | 3796 | 3649 | 534 | 543 | 8522 |
16 further baseline measures are reported on the registry.
Showing the first 100 of 256 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2009, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clopidogrel · Aspirin · Prasugrel
Baim Institute for Clinical Research